1. Home
  2. Analysis
  3. Ofev
  4. Ranexa

Ofev and Ranexa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ofev (nintedanib esylate) and Ranexa (ranolazine). Common drug interactions include diarrhoea among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Ofev and Ranexa. It is created by eHealthMe based on reports of 28 people who take the same drugs from the FDA, and is updated regularly.

What is Ofev?

Ofev has active ingredients of nintedanib esylate. eHealthMe is studying from 24,791 Ofev users. Check the latest studies of Ofev.

What is Ranexa?

Ranexa has active ingredients of ranolazine. It is often used in angina. eHealthMe is studying from 11,758 Ranexa users. Check the latest studies of Ranexa.

On Jul, 11, 2026

28 people who take Ofev and Ranexa together, and have interactions are studied.

Ofev and Ranexa drug interactions.

What are the common drug interactions of Ofev and Ranexa, by gender? *:

female:

  1. Diarrhoea
  2. Abdominal pain upper
  3. Decreased appetite
  4. Weight decreased
  5. Abdominal discomfort
  6. Dehydration (dryness resulting from the removal of water)
  7. Asthenia (weakness)
  8. Blood glucose decreased
  9. Blood pressure increased
  10. Constipation

male:

  1. Diarrhoea
  2. Nausea (feeling of having an urge to vomit)
  3. Dizziness
  4. Rhinorrhoea (watery mucus discharge from the nose)
  5. Frequent bowel movements
  6. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  7. Dyspnoea (difficult or laboured respiration)
  8. Cardiac failure congestive
  9. Pain
  10. Asthenia (weakness)

What are the common drug interactions of Ofev and Ranexa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Diarrhoea
  2. Nausea (feeling of having an urge to vomit)
  3. Rhinorrhoea (watery mucus discharge from the nose)
  4. Frequent bowel movements
  5. Dizziness
  6. Dyspnoea (difficult or laboured respiration)
  7. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  8. Abdominal pain upper
  9. Asthenia (weakness)
  10. Cardiac failure congestive

What are the existing conditions these people have? *

  1. Idiopathic Pulmonary Fibrosis (chronic lung disease): 28 people, 100.00%
  2. Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 7.14%
  3. High Blood Cholesterol: 2 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Ofev and Ranexa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ofev and Ranexa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ofev:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ranexa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ofev and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ranexa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on nintedanib esylate and ranolazine (the active ingredients of Ofev and Ranexa, respectively), and Ofev and Ranexa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.